Summary: Virax Biolabs has extended its exclusive distribution agreement with Cosmos Health Inc. to commercialize its Mpox Virus Real-Time PCR Detection Kits in the Gulf Cooperation Council, expanding its reach from Europe to the Middle East.
Takeaways:
- Virax Biolabs’ partnership with Cosmos Health now covers the exclusive distribution of its Mpox RT-PCR detection kits in countries within the Gulf Cooperation Council, including Saudi Arabia and the UAE.
- The kits, already CE-marked and authorized by the UK’s MHRA, offer high accuracy with 96.7% sensitivity and 93.72% specificity, providing results in under 70 minutes.
- This expanded agreement positions both companies to meet the growing demand for reliable Mpox virus testing, furthering efforts to control the spread of infectious diseases.
Virax Biolabs, a biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, entered into an extension of its already existing exclusive distribution agreement with Cosmos Health Inc. to commercialize Mpox Virus Real-Time PCR Detection Kits in countries in the Gulf Cooperation Council. It had previously signed an agreement for exclusive distribution in Greece & Cyrprus and non-exclusive distribution throughout Europe.
Mpox Detection Kits
The RT PCR Mpox virus detection kits are CE-marked for sale in Europe and also authorized by the Medicines and Healthcare products Regulatory Agency (MHRA), the product regulatory agency for the United Kingdom. These tests perform with a sensitivity of 96.7% and specificity of 93.72%, with the ability to deliver results in under 70 minutes.
“We are excited to strengthen our partnership with Cosmos. This exclusive agreement expands our geographic reach, providing a wider network of healthcare professionals with essential tools to diagnose and manage the spread of the Mpox virus,” says James Foster, CEO of Virax Biolabs. “We look forward to working closely with Cosmos and leveraging its impressive distribution infrastructure.”
Further reading: Virax Biolabs Announces Distribution Agreement for Mpox RT-PCR Kits in Europe, Middle East
“We are happy to further partner with Virax Biolabs as the Company works diligently to mitigate the spread of Mpox and other infectious diseases,” says Greg Siokas, Chief Executive Officer of Cosmos. “We continue to see strong demand for Mpox virus detection kits, and we believe that we are well positioned to support Virax and territories in need.”
Under the terms of the agreement, Cosmos is authorized to import, sell and distribute Virax-branded Mpox virus Nucleic Acid Detection Kits in the Gulf Cooperation Council including Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates.
